

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Gazyva

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:			
Member/Subscriber Number:	Fax:	Phone:		
Date of Birth:	Office Contact:	i none.		
Group Number:	NPI:	State Lic ID:		
Address:	Address:	Otato Elo ID.		
City, State ZIP:	City, State ZIP:			
Primary Phone:	Specialty/facility name (if applicable)	:		
Drug Name and Strength:				
Directions / SIG:				
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.				
Q1. Is the prescribing physician a hematologist or oncolog ☐ Yes ☐ No	ist?			
Q2. For what diagnosis is the drug being prescribed (pick	one)?			
☐ Chronic lymphocytic leukemia (CLL), previously untreated				
☐ Follicular lymphoma (FL)				
Other				
Q3. Please provide ICD code(s) for diagnosis				
Q4. Please indicate location of administration.				
☐ Home				
☐ Long Term Care (LTC) facility				
☐ Physician office (drug from office stock - buy and bill)				
☐ Physician office (drug from pharmacy with a prescription	on)			
Q5. If using for CLL, is member using Gazyva as first-line	therapy?			
☐ Yes ☐ No				



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Gazyva

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

		Dragarihar N	Jamas	
Patient Name:		Prescriber N		
ratient Name.			Supervising Physician:	
Q6. If using for CI	LL, will Gazyva be used in con	nbination with chloramb	ucil?	
☐ Yes	☐ No			
Q7. If using for FL	, did the patient relapse after	or is the patient refracto	ry to a rituximab-containing regimen?	
☐ Yes	☐ No			
Q8. If using for FL	., will Gazyva be used in comb	bination with bendamust	ine followed by Gazyva monotherapy?	
☐ Yes	☐ No			
Q9. Additional cor	mments			
<u> </u>				
	Prescriber Signature		Date	
- " "				
	,		at applying the standard review timeframe may ity to regain maximum function	
			Requesting providers may speak to the SWHP medical act the decision on a request before coverage has beer	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document